Beijing Biotech

Biotech Pharmaceutical Co., Ltd. (BPL) is a prominent Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative monoclonal antibodies and therapeutic vaccines for oncology and autoimmune diseases. Established in 2000 as a strategic high-tech joint venture between China and Cuba, the company operates one of China's largest and most advanced mammalian cell culture facilities. BPL's flagship product, Nimotuzumab (Taixinsheng), was the first humanized monoclonal antibody approved in China for the treatment of nasopharyngeal cancer and has since been included in the National Medical Insurance Catalogue. The company maintains a robust clinical pipeline, including late-stage trials for Nimotuzumab in multiple solid tumor indications and an innovative EGF vaccine for lung cancer. Headquartered in the Beijing Economic-Technological Development Area, BPL is a key player in China's transition toward independent innovation in the life sciences sector.